Human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine is under clinical development by Chengdu Institute of Biological Products and currently in Phase III for Human Papillomavirus Infections. According to GlobalData, Phase III drugs for Human Papillomavirus Infections have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine overview
The vaccine candidate is under investigation for the prevention of human papilloma virus infections. It is administered through intramuscular route. The drug candidate is a recombinant tetravalent vaccine comprising four serotypes (6,11,16,18) of HPV.
See Also:
Chengdu Institute of Biological Products overview
Chengdu Institute of Biological Products (CDIBP) focuses on research of medical microbiology, cytology and immunology, producing biological products. CDIBP is headquartered in Chengdu, Chongqing, China.
For a complete picture of Human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.